FDA Approves Test for Hematologic Cancer Detection

Data presented at the 2017 American Society of Hematology Annual Meeting support mutated calreticulin (CALR) as an MPN-specific tumor antigen, paving the way for immunotherapies targeting this mutation for patients with MPN.

Cancer Network